title: Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
abstract: OBJECTIVE
  To synthesize mesoporous silica-core-shell magnetic nanoparticles (MNPs) encapsulated by liposomes (Lipo [MNP@m-SiO2]) in order to enhance their stability, allow them to be used in any buffer solution, and to produce trastuzumab-conjugated (Lipo[MNP@m-SiO2]-Her2Ab) nanoparticles to be utilized in vitro for the targeting of breast cancer.
  
  
  METHODS
  The physiochemical characteristics of Lipo[MNP@m-SiO2] were assessed in terms of size, morphological features, and in vitro safety. The multimodal imaging properties of the organic dye incorporated into Lipo[MNP@m-SiO2] were assessed with both in vitro fluorescence and MR imaging. The specific targeting ability of trastuzumab (Her2/neu antibody, Herceptin®)-conjugated Lipo[MNP@m-SiO2] for Her2/neu-positive breast cancer cells was also evaluated with fluorescence and MR imaging.
  
  
  RESULTS
  We obtained uniformly-sized and evenly distributed Lipo[MNP@m-SiO2] that demonstrated biological stability, while not disrupting cell viability. Her2/neu-positive breast cancer cell targeting by trastuzumab-conjugated Lipo[MNP@m-SiO2] was observed by in vitro fluorescence and MR imaging.
  
  
  CONCLUSIONS
  Trastuzumab-conjugated Lipo[MNP@m-SiO2] is a potential treatment tool for targeted drug delivery in Her2/neu-positive breast cancer.
authors: Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.
authors: Mijung
authors: M
authors: Jang
authors: Nanoimaging and Therapy Research Center, Institute of Nanoconvergence, Advanced Institutes of Convergence Technology, Seoul National University, Suwon 443-270, Korea.
authors: Young Il
authors: YI
authors: Yoon
authors: NanoBio Materials Chemistry Lab., Department of Applied Bioscience, CHA University, Pocheon 487-010, Korea.
authors: Yong Soo
authors: YS
authors: Kwon
authors: Nanoimaging and Therapy Research Center, Institute of Nanoconvergence, Advanced Institutes of Convergence Technology, Seoul National University, Suwon 443-270, Korea. ; NanoBio Materials Chemistry Lab., Department of Applied Bioscience, CHA University, Pocheon 487-010, Korea.
authors: Tae-Jong
authors: TJ
authors: Yoon
authors: Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea. ; Nanoimaging and Therapy Research Center, Institute of Nanoconvergence, Advanced Institutes of Convergence Technology, Seoul National University, Suwon 443-270, Korea. ; Program in Nano Science and Technology, Department of Transdisciplinary Studies, Seoul National University Graduate School of Convergence Science and Technology, Suwon 443-270, Korea.
authors: Hak Jong
authors: HJ
authors: Lee
authors: Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.
authors: Sung Il
authors: SI
authors: Hwang
authors: Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.
authors: Bo La
authors: BL
authors: Yun
authors: Department of Radiology, Seoul National University Bundang Hospital, Seongnam 463-707, Korea.
authors: Sun Mi
authors: SM
authors: Kim
mesh_terms: D016475:3T3 Cells; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D005290:Ferric Compounds / Q000737:chemistry; D006801:Humans; D008081:Liposomes; D058185:Magnetite Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods; D058726:Nanoconjugates / Q000008:administration & dosage / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D012822:Silicon Dioxide / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000737:chemistry; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D005290:Ferric Compounds; D008081:Liposomes; D058185:Magnetite Nanoparticles; D058726:Nanoconjugates; D018719:Erb-b2 Receptor Tyrosine Kinases; D012822:Silicon Dioxide; D000068878:Trastuzumab; C000499:ferric oxide
keywords: Breast cancer; Drug delivery; Iron oxide nanoparticles; Magnetic resonance imaging; Trastuzumab